Tumour board

What it is

A tumour board is a multidisciplinary cancer meeting where specialists review a case together to recommend treatment, and a 2020 umbrella review found the strongest evidence for better diagnostic and treatment planning rather than a clear survival benefit. You may also hear it called a tumour board, multidisciplinary tumour board, or multidisciplinary team meeting. The main idea is simple: instead of one doctor making a plan alone, several experts discuss the same case at the same time.

A typical tumour board may include a medical oncologist, surgical oncologist, radiation oncologist, radiologist, pathologist, and sometimes palliative care, genetics, nursing, nutrition, psycho-oncology, or site-specific specialists. The group reviews the patient history, scans, biopsy results, stage, performance status, and treatment goals. It then gives a consensus recommendation, which is usually documented in the medical record.

For patients and families, the most important fact is that a tumour board is usually an advisory step in care planning, not a treatment itself. The final plan still depends on the patient's condition, preferences, test results, logistics, and discussion with the treating team. In India, this model is common in larger cancer centres and academic hospitals, especially for complex, rare, or borderline-operable cancers.

Common name	What it means
Tumour board	General term for a multidisciplinary cancer case discussion
MDT meeting	Multidisciplinary team meeting; common UK-style term
MTB	Multidisciplinary tumour board; often used in journals and hospitals
Molecular tumour board	A board focused on genomic or biomarker findings and targeted therapy options

How it works

A tumour board usually meets on a fixed schedule, such as weekly, and discusses new, difficult, or changing cases. Before the meeting, the team gathers key information such as pathology slides, imaging, blood tests, staging details, prior treatments, and current symptoms. During the meeting, each specialist comments from their own area.

For example, the radiologist may clarify whether a lesion looks operable, the pathologist may confirm tumour type and grade, the surgeon may discuss resectability, and the medical or radiation oncologist may compare chemotherapy, immunotherapy, targeted therapy, or radiotherapy options. If needed, the board may recommend more tests before treatment starts, such as repeat biopsy, PET-CT, molecular profiling, or review of pathology.

Many centres use tumour boards for decisions such as:

1. Confirming diagnosis and stage
2. Deciding whether surgery should come first
3. Choosing neoadjuvant or adjuvant treatment
4. Reviewing recurrence or metastatic disease
5. Considering clinical trials or precision oncology options

A molecular tumour board is a more specialised version. It focuses on genomic reports, biomarkers, and whether a mutation is actionable. This can matter in advanced cancers, but access, cost, and evidence vary by tumour type and by hospital.

Evidence and uses

Tumour boards are widely used because cancer care often needs input from several specialties. The evidence suggests they can improve process measures, especially diagnostic accuracy, staging, adherence to guidelines, and changes in treatment plans. Reviews have found that discussion in a tumour board can lead to a meaningful proportion of cases having their diagnosis, stage, or management plan revised after imaging or pathology is re-reviewed.

The 2020 umbrella review on tumour boards concluded that benefits are most consistent for care processes and decision-making quality. Evidence for direct effects on survival, however, is less certain and mixed. That does not mean tumour boards are unhelpful. It means survival depends on many factors, including cancer type, stage, biology, access to treatment, and how quickly recommendations are carried out.

A 2022 review focused on breast cancer also found that multidisciplinary boards can improve coordination and guideline-concordant care, but the size of benefit differs across studies. Some studies show shorter time to treatment or more appropriate use of surgery and radiotherapy, while others show smaller effects. Research is also complicated because hospitals with tumour boards may already have better systems overall.

Common situations where a tumour board is especially useful include:

Situation	Why board review helps
New cancer diagnosis	Confirms pathology, stage, and first-line plan
Rare cancer	Brings together limited expertise from different specialties
Borderline operable tumour	Helps decide surgery vs chemotherapy/radiotherapy first
Recurrence	Reassesses prior treatment and new options
Advanced cancer with biomarkers	Reviews targeted therapy, immunotherapy, or trial eligibility
Need for palliation	Coordinates symptom control with disease-directed treatment

In India, tumour boards can be particularly helpful when patients move between local hospitals and tertiary cancer centres. A board discussion may reduce fragmented decision-making and help align surgery, systemic therapy, radiation, pathology review, and supportive care. Still, availability differs widely between metro cancer centres and smaller hospitals.

When to see a clinician

You do not need to request a tumour board for every cancer case, but it is reasonable to ask whether your case has been or can be discussed in one, especially if the diagnosis is new, uncommon, advanced, recurrent, or if doctors have suggested more than one possible treatment path.

Ask your treating clinician about tumour board review if:

• your biopsy or scan findings are unclear
• surgery, chemotherapy, and radiation are all being considered
• you have been told the tumour is borderline operable or inoperable
• the cancer has returned after treatment
• genomic testing shows a mutation and you want to know whether it changes treatment
• you want a second opinion within the same hospital system

Useful questions include: Which specialists will review my case? Will my scans and pathology be re-read? What recommendation came out of the meeting? Does the board recommendation match standard guidelines? If not, why?

Patients usually do not attend the meeting itself, though practices vary by hospital. The results are generally explained afterward by the treating doctor.

Limitations and open questions

Tumour boards are important, but they are not perfect. The quality of the recommendation depends on who is present, how complete the case information is, whether pathology and imaging are available for review, and whether the hospital can actually deliver the recommended treatment. A strong recommendation on paper may still be hard to carry out because of cost, travel, waiting times, or limited local services.

Evidence also has limits. Many studies are observational rather than randomised, so it is hard to prove that the tumour board alone caused better outcomes. Definitions differ between studies, and some boards are highly structured while others are informal. This makes results harder to compare.

Another open question is how to measure success. Better survival is the most important outcome, but not the only one. A tumour board may still add value by improving diagnosis, reducing unnecessary treatment, identifying clinical trials, or making care more consistent with guidelines. Evidence in humans supports these process benefits more clearly than it proves a survival advantage.

Molecular tumour boards raise additional questions about cost-effectiveness, access to genomic testing, and whether an actionable mutation truly leads to a useful treatment in a given setting. This is especially relevant in lower-resource settings, including many parts of India.

A tumour board should support shared decision-making, not replace it. The best plan is the one that is medically sound, feasible, and aligned with the patient's goals.